On the physiological side, follow-up studies will have to demonstrate a predicted improved therapeutic benefit may take place, when co-administering GCs and PPARα agonists in an animal model of chronic inflammation (e.g., multiple sclerosis, arthritis, or asthma). The gene discussed is PPARA; the disease is multiple sclerosis.